You are here: Industry Insights > Novartis

News List

Novartis slaps $2M-plus price tag on newly approved gene therapy Zolgensma—and cost watchdogs approve fiercepharma
May 29, 2019
Industry watchers have been speculating for months about just how high Novartis would price gene therapy Zolgensma on approval—and just how payers would cover it. And with the FDA’s green light, they now have an answer.
FDA approval for Novartis’ Piqray pharmatimes
May 28, 2019
Novartis’ Piqray (alpelisib) has been approved by the US Food and Drug Administration (FDA) in combination with fulvestrant for the treatment of postmenopausal women and men with HR+ and HER2- PIK3CA-mutated, advanced or metastatic breast cancer.
Novartis phase II data for new inhaled combination treatment (QVM149) demonstrates significant improvements over current standard-of-care inhaled treatment worldpharmanews
May 24, 2019
Novartis announced today that new phase II data for IND/GLY/MF (QVM149), an investigational, once-daily, fixed dose combination asthma treatment containing indacaterol acetate ...
GSK and Novartis ‘misled’ consumers, says Federal Court of Australia europeanpharmaceuticalreview
May 21, 2019
GSK and Novartis found to have misled consumers with the packaging and pricing of their osteoarthritis pain treatment.
Novartis Issues Voluntary Nationwide Recall of Promacta 12.5 mg for Oral Suspension Due to Potential Peanut Contamination drugs
May 20, 2019
Novartis Issues Voluntary Nationwide Recall of Promacta 12.5 mg for Oral Suspension Due to Potential Peanut Contamination.
Novartis' Kymriah to be covered by Japan's national insurance system pharmafile
May 17, 2019
Japan’s national medical insurance system will pay for Novartis’ CAR-T therapy Kymriah following approval from the Central Social Insurance Medical Council.
Novartis Issues Recall of Promacta® 12.5 mg for Oral Suspension americanpharmaceuticalreview
May 16, 2019
Novartis has announced a voluntary recall of three lots of Promacta (eltrombopag) 12.5 mg for oral suspension to the consumer level.
Novartis’ slow-rolling Kymriah wins coverage in Japan at $305K: report fiercepharma
May 16, 2019
After snagging the first Japanese CAR-T approval in March, Novartis has won the go-ahead to sell its groundbreaking med, Kymriah, under the country’s national insurance system. And that gives the brand a chance to boost lagging sales.
Novartis Buys Dry Eye Drug from Takeda for $5.3B contractpharma
May 16, 2019
Takeda also divests TachoSil to Ethicon for $400 million.
Codexis, Novartis Ink Tech Transfer and License Agreement contractpharma
May 16, 2019
Novartis to leverage CodeEvolver protein engineering platform technology develop performance enzymes for use in manufacturing.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 71 72 Next page